FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1979655862> ?p ?o ?g. }

• W1979655862 endingPage "124" @default.
• W1979655862 startingPage "107" @default.
• W1979655862 abstract "Skin carcinogenesis can be operationally and mechanistically divided into at least three stages; tumor initiation, stage I and stage II of promotion. Current information suggests that reactive intermediates of skin tumor initiators are mutagenic and bind convalently to DNA of epidermal stem cells (dark basal keratinocytes) leading to some irreversible alteration in the differentiation capacity of these cells. Inhibitors of skin tumor initiation by polycyclic aromatic hydrocarbons (PAH) decrease the level of the PAH diol-epoxide bound to specific DNA adducts. The tumor promoters have been shown to have many cellular and biochemical effects in the skin. Recent data suggests that free radicals may be important in skin tumor promotion. The first stage of promotion is partially irreversible and can be accomplished by a single treatment of a tumor promoter such as TPA or by non-promoting agents such as 4-0-methyl-TPA, calcium ionophore A23187, and hydrogen peroxide, as well as wounding. These agents increase the number of dark basal keratinocytes, which suggest that these cells are important in the first stage of promotion. Prostaglandin E2 was found to specifically enhance stage I of promotion whereas the protease inhibitor tosyl phenylalanine chloromethylketone (TPCK) specially inhibited stage I of promotion and the TPA-induced dark basal keratinocytes. The second stage of promotion is initially reversible but later becomes irreversible. The weak promoting agent mezerein is an effective stage II promoter. Polyamines and epidermal cell proliferation appear to be important events in stage II of promotion. Putrescine was found to specifically enhance stage II, whereas retinoic acid (RA), diflouromethylornithine (DFMO), and butylated hydroxyanisole (BHA) specially inhibited stage II of promotion and the mezerein-induced polyamine levels. Floucinolone acetonide (FA) was found to inhibit both stages but was more effective in counteracting stage I of promotion. Although, TPA can cause a decrease in the number of glucocorticoid receptors during promotion, FA can effectively prevent this loss. Recent data suggest that skin tumor promotion can be effectively inhibited by a combination of stage I and II inhibitors. Furthermore, skin carcinogenesis can be counteracted by a combination of low and nontoxic doses of BHA, TPCK, DFMO and vitamin E." @default.
• W1979655862 created "2016-06-24" @default.
• W1979655862 creator A5076209858 @default.
• W1979655862 date "2009-03-13" @default.
• W1979655862 modified "2023-10-10" @default.
• W1979655862 title "Chapter 7: MULTISTAGE SKIN CARCINOGENESIS: A USEFUL MODEL FOR THE STUDY OF THE CHEMOPREVENTION OF CANCER" @default.
• W1979655862 cites W1980008992 @default.
• W1979655862 cites W1986270436 @default.
• W1979655862 cites W2005740472 @default.
• W1979655862 cites W2087533996 @default.
• W1979655862 doi "https://doi.org/10.1111/j.1600-0773.1984.tb02485.x" @default.
• W1979655862 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6385617" @default.
• W1979655862 hasPublicationYear "2009" @default.
• W1979655862 type Work @default.
• W1979655862 sameAs 1979655862 @default.
• W1979655862 citedByCount "31" @default.
• W1979655862 countsByYear W19796558622012 @default.
• W1979655862 countsByYear W19796558622013 @default.
• W1979655862 countsByYear W19796558622014 @default.
• W1979655862 countsByYear W19796558622015 @default.
• W1979655862 countsByYear W19796558622016 @default.
• W1979655862 countsByYear W19796558622017 @default.
• W1979655862 countsByYear W19796558622018 @default.
• W1979655862 countsByYear W19796558622022 @default.
• W1979655862 countsByYear W19796558622023 @default.
• W1979655862 crossrefType "journal-article" @default.
• W1979655862 hasAuthorship W1979655862A5076209858 @default.
• W1979655862 hasConcept C104317684 @default.
• W1979655862 hasConcept C185592680 @default.
• W1979655862 hasConcept C2778287671 @default.
• W1979655862 hasConcept C2780122803 @default.
• W1979655862 hasConcept C502942594 @default.
• W1979655862 hasConcept C55493867 @default.
• W1979655862 hasConcept C555283112 @default.
• W1979655862 hasConcept C86803240 @default.
• W1979655862 hasConceptScore W1979655862C104317684 @default.
• W1979655862 hasConceptScore W1979655862C185592680 @default.
• W1979655862 hasConceptScore W1979655862C2778287671 @default.
• W1979655862 hasConceptScore W1979655862C2780122803 @default.
• W1979655862 hasConceptScore W1979655862C502942594 @default.
• W1979655862 hasConceptScore W1979655862C55493867 @default.
• W1979655862 hasConceptScore W1979655862C555283112 @default.
• W1979655862 hasConceptScore W1979655862C86803240 @default.
• W1979655862 hasIssue "S2" @default.
• W1979655862 hasLocation W19796558621 @default.
• W1979655862 hasLocation W19796558622 @default.
• W1979655862 hasOpenAccess W1979655862 @default.
• W1979655862 hasPrimaryLocation W19796558621 @default.
• W1979655862 hasRelatedWork W108085202 @default.
• W1979655862 hasRelatedWork W1598305631 @default.
• W1979655862 hasRelatedWork W1991110338 @default.
• W1979655862 hasRelatedWork W1996126939 @default.
• W1979655862 hasRelatedWork W2026398700 @default.
• W1979655862 hasRelatedWork W2137615558 @default.
• W1979655862 hasRelatedWork W2317948309 @default.
• W1979655862 hasRelatedWork W2412820367 @default.
• W1979655862 hasRelatedWork W2465265569 @default.
• W1979655862 hasRelatedWork W334176592 @default.
• W1979655862 hasVolume "55" @default.
• W1979655862 isParatext "false" @default.
• W1979655862 isRetracted "false" @default.
• W1979655862 magId "1979655862" @default.
• W1979655862 workType "article" @default.